ストックスクリーナーアプリを入手
10.19
9.82%
-1.11
前日終値:
$11.30
開ける：
$11.25
24時間の取引高:
30,421
Relative Volume:
1.26
時価総額：
$21.15M
収益：
-
当期純損益:
$-4.85M
株価収益率:
-32.87
EPS:
-0.31
ネットキャッシュフロー:
$-3.95M
1週間 パフォーマンス:
-12.23%
1か月 パフォーマンス:
-22.83%
6か月 パフォーマンス:
-35.10%
1年 パフォーマンス:
-27.27%
1日の値動き範囲:
$10.01
$11.28
1週間の範囲:
$10.01
$12.22
52週間の値動き範囲:
$8.74
$22.90
Cadrenal Therapeutics Inc Stock (CVKD) Company Profile
CVKD を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CVKD
Cadrenal Therapeutics Inc
|
10.19 | 23.46M | 0 | -4.85M | -3.95M | -0.31 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.76 | 107.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
755.90 | 77.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
436.38 | 58.90B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
918.92 | 56.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
198.76 | 42.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
Cadrenal Therapeutics Inc Stock (CVKD) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2023-12-18 | 開始されました | Noble Capital Markets | Outperform |
Cadrenal Therapeutics Inc (CVKD) 最新ニュース
Precision Trading with Cadrenal Therapeutics Inc. (CVKD) Risk Zones - news.stocktradersdaily.com
Why Cadrenal Therapeutics Inc. stock could see breakout soonJuly 2025 Spike Watch & Growth Focused Stock Reports - newser.com
Institutional scanner results for Cadrenal Therapeutics Inc.2025 Earnings Impact & Step-by-Step Trade Execution Guides - newser.com
Is Cadrenal Therapeutics Inc. stock a good choice for value investors2025 Sector Review & Safe Entry Zone Tips - newser.com
Cadrenal Therapeutics CEO, Quang X. Pham, Receives BioFlorida’s Executive of the Year Award - The Manila Times
Agilent Technologies (NYSE: A) Debuts Altura Ultra Inert HPLC With 2x Sensitivity - Stock Titan
Detecting price anomalies in Cadrenal Therapeutics Inc. with AITreasury Yields & Fast Gaining Stock Reports - newser.com
What the charts say about Cadrenal Therapeutics Inc. todayWatch List & Daily Stock Trend Watchlist - newser.com
Is Cadrenal Therapeutics Inc. stock attractive for retirement portfolios2025 Breakouts & Breakdowns & Risk Managed Investment Entry Signals - newser.com
Cadrenal Therapeutics Receives Legal Opinion From Blank Rome LLP On ?Validity Of Share Offering - MarketScreener
Cadrenal Therapeutics Announces New Stock Offering Program - TipRanks
Cadrenal Therapeutics IncBlank Rome LLP issued legal opinion on $3,438,062 sharesSEC filing - MarketScreener
[8-K] Cadrenal Therapeutics, Inc. Reports Material Event | CVKD SEC FilingForm 8-K - Stock Titan
Price momentum metrics for Cadrenal Therapeutics Inc. explainedDividend Hike & AI Forecast for Swing Trade Picks - newser.com
Quantitative breakdown of Cadrenal Therapeutics Inc. recent move2025 Major Catalysts & Growth Focused Entry Reports - newser.com
What institutional flow reveals about Cadrenal Therapeutics Inc.Insider Selling & Verified Entry Point Signals - newser.com
Combining machine learning predictions for Cadrenal Therapeutics Inc.July 2025 Review & Capital Protection Trading Alerts - newser.com
Is Cadrenal Therapeutics Inc. stock cheap compared to fundamentalsJuly 2025 Review & Low Drawdown Trading Strategies - newser.com
Will Cadrenal Therapeutics Inc. stock outperform value stocksWeekly Investment Recap & Technical Entry and Exit Tips - Fundação Cultural do Pará
What to do if you’re stuck in Cadrenal Therapeutics Inc.2025 Year in Review & Real-Time Stock Price Movement Reports - newser.com
Technical Reactions to CVKD Trends in Macro Strategies - news.stocktradersdaily.com
Is CLNN stock oversold or undervaluedTake Profit & Precise Swing Trade Entry Alerts - newser.com
Will Cadrenal Therapeutics Inc. see short term momentumEarnings Risk Summary & Expert Curated Trade Setup Alerts - newser.com
Cadrenal Therapeutics Reports Increased Losses Amid Strategic Expansion - The Globe and Mail
Cadrenal Therapeutics, Inc. Reports Q3 2025 Financial Results and Clinical Development Updates on Tecarfarin and Frunexian - Quiver Quantitative
Cadrenal Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update - The Manila Times
Cadrenal (NASDAQ: CVKD) adds Phase 2-ready frunexian; updates cGMP tecarfarin - Stock Titan
Cadrenal Therapeutics, Inc. SEC 10-Q Report - TradingView
Cadrenal Therapeutics Inc (CVKD) 財務データ
収益
当期純利益
現金流量
EPS
1.38%
1.42%
大文字化:
|
ボリューム (24 時間):